Ketoconazole and sulphaphenazole as the respective selective inhibitors of p4503a and 2c9

Xenobiotica

Volumn 25, Issue 3, 1995, Pages 261-270

  Baldwin, S J ^a   Bloomer, J C ^a   Smith, G J ^a   Ayrton, A D ^a   Clarke, S E ^a   Chenery, R J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; KETOCONAZOLE; OXIDOREDUCTASE; OXYGENASE; SULFAPHENAZOLE; TOLBUTAMIDE;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE;

CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMAN; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEROID HYDROXYLASES; SULFAPHENAZOLE; TOLBUTAMIDE;

EID: 0028970047     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259509061850     Document Type: Article

References (58)

1. Cortisol metabolism in vitro. III. Inhibition of microsomal 6β-hydroxylase and cytosolic 4-ene-reductase
2. Sulphaphenazole and drug oxidation in man
3. Comparative effects of two antimycotic agents ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cycloporine and ethoxycoumarin by human liver microsomes in vitro
4. Azoles, allylamines and drug metabolism
5. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines
6. Evidence for the involvement of several cytochromes P-450 in the steps of caffeine metabolism by human liver microsomes
7. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in
8. Ketoconazole inhibition of oxidative drug metabolism: effect of age and gender
9. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450
10. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes
11. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetes
12. Characterization of the inhibition of P4501A2 by furafylline
13. Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes
14. Metabolism of cyclosporin A. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily
15. Clinical pharmacokinetics of ketoconazole
16. A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog
17. Lauric acid hydroxylase activity and cytochrome P450 IV family proteins in human liver microsomes
18. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes
19. Evidence of CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions
20. Ketoconazole, cyclosporin metabolism and renal transplantation
21. Cyclosporine-ketoconazole interaction
22. Purification and characterization of liver microsomal cytochrome P-450 from untreated male rats
23. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam
24. Nephrotoxicity of cyclosporin A in bone-marrow transplantation
25. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion
26. Ketoconazole: a major innovation for treatment of fungal disease
27. Mechanism-based inactivation of human liver microsomal cytochrome P450 IIIA4 by gestodene
28. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6β-hydroxylation of testosterone in human liver microsomes
29. Ketoconazole: a review of its therapeutic efficacy in superficial and systematic fungal infections
30. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes
31. Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture
32. Drug interactions that matter. A critical reappraisal
33. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography
34. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro
35. Tolbutamide hydroxylation by human liver microsomes, kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations
36. The P450 superfamily: update on the new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature
37. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes
38. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
39. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenylbutazone, sulfaphenazole
40. Ketoconazole blocks testosterone synthesis
41. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
42. Characterization of theophylline metabolism by human liver microsomes
43. Kinetics of tolbutamide interactions
44. Ketoconazole: A potent inhibitor of cytochrome P450-dependent drug metabolism in rat liver
45. Measurement of protein using bicinchoninic acid
46. The use of ketoconazole as an inhibitor of steroid production
47. Ketoconazole inhibits hepatic oxidative drug metabolism
48. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine
49. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
50. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily
51. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450
52. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation
53. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
54. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man
55. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions